ACCOUNTS - Final Accounts preparation


Caseware UK (AP4) 2020.0.247 2020.0.247 2020-09-302020-09-302021-05-212019-09-04No description of principal activity1false0falseThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006. 12189862 2019-09-03 12189862 2019-09-04 2020-09-30 12189862 2018-09-04 2019-09-03 12189862 2020-09-30 12189862 c:Director1 2019-09-04 2020-09-30 12189862 d:CurrentFinancialInstruments 2020-09-30 12189862 c:Micro-entities 2019-09-04 2020-09-30 12189862 c:AuditExempt-NoAccountantsReport 2019-09-04 2020-09-30 12189862 c:FullAccounts 2019-09-04 2020-09-30 12189862 c:PrivateLimitedCompanyLtd 2019-09-04 2020-09-30 iso4217:GBP xbrli:pure
Registered number: 12189862



MOLECULES TO MEDICINES LTD








UNAUDITED
FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 30 SEPTEMBER 2020














img1165.png

 
MOLECULES TO MEDICINES LTD
REGISTERED NUMBER: 12189862

STATEMENT OF FINANCIAL POSITION
AS AT 30 SEPTEMBER 2020

2020
£


Fixed assets
3,243

Current assets
52,100

Creditors: amounts falling due within one year
(14,356)

Net current assets
 
 
37,744

Total assets less current liabilities
40,987


Net assets
40,987



Capital and reserves
40,987


Notes

General information

The principal activity of Molecules to Medicines Limited is biotechnology research.
The company incorporated on 4 September 2019 and commenced trading on that date.
The company is a private company limited by shares and is incorporated in England and Wales.
The registered office address is 27 Charlotte Avenue, Fairfield Park, Hitchin, SG5 4GQ.




Average number of employees

The average monthly number of employees, including directors, during the period was 1.




The director considers that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the period in question in accordance with section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared in accordance with the provisions applicable to entities subject to the micro-entities' regime.
 
Page 1

 
MOLECULES TO MEDICINES LTD
REGISTERED NUMBER: 12189862
    
STATEMENT OF FINANCIAL POSITION (CONTINUED)
AS AT 30 SEPTEMBER 2020


The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 




................................................
N Miller
Director

Date: 21 May 2021

 
Page 2